132 related articles for article (PubMed ID: 9893669)
21. Gene expression in X-irradiated human tumour cell lines expressing cisplatin resistance and altered DNA repair capacity.
Taverna P; Hansson J; Scanlon KJ; Hill BT
Carcinogenesis; 1994 Sep; 15(9):2053-6. PubMed ID: 7923602
[TBL] [Abstract][Full Text] [Related]
22. Cell cycle checkpoint abrogator UCN-01 inhibits DNA repair: association with attenuation of the interaction of XPA and ERCC1 nucleotide excision repair proteins.
Jiang H; Yang LY
Cancer Res; 1999 Sep; 59(18):4529-34. PubMed ID: 10493501
[TBL] [Abstract][Full Text] [Related]
23. Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines.
Arnould S; Hennebelle I; Canal P; Bugat R; Guichard S
Eur J Cancer; 2003 Jan; 39(1):112-9. PubMed ID: 12504667
[TBL] [Abstract][Full Text] [Related]
24. Irofulven cytotoxicity depends on transcription-coupled nucleotide excision repair and is correlated with XPG expression in solid tumor cells.
Koeppel F; Poindessous V; Lazar V; Raymond E; Sarasin A; Larsen AK
Clin Cancer Res; 2004 Aug; 10(16):5604-13. PubMed ID: 15328203
[TBL] [Abstract][Full Text] [Related]
25. Expression of domains for protein-protein interaction of nucleotide excision repair proteins modifies cancer cell sensitivity to platinum derivatives and genomic stability.
Jordheim LP; Cros-Perrial E; Matera EL; Bouledrak K; Dumontet C
Clin Exp Pharmacol Physiol; 2014 Oct; 41(10):817-24. PubMed ID: 25115435
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of the two nucleotide excision repair genes ERCC1 and XPC in human hepatocellular carcinoma.
Fautrel A; Andrieux L; Musso O; Boudjema K; Guillouzo A; Langouët S
J Hepatol; 2005 Aug; 43(2):288-93. PubMed ID: 15922480
[TBL] [Abstract][Full Text] [Related]
27. Loss of heterozygosity of nucleotide excision repair factors in sporadic ovarian, colon and lung carcinomas: implication for their roles of carcinogenesis in human solid tumors.
Takebayashi Y; Nakayama K; Kanzaki A; Miyashita H; Ogura O; Mori S; Mutoh M; Miyazaki K; Fukumoto M; Pommier Y
Cancer Lett; 2001 Dec; 174(2):115-25. PubMed ID: 11689286
[TBL] [Abstract][Full Text] [Related]
28. Combining Phenotypes of Nucleotide Excision Repair Pathway to Predict the Risk of Head and Neck Squamous Cell Carcinomas in a Chinese Population.
Liang Y; Zhang L; Chen Z; Chen J; Fang S; Zhang T; Zhu Y; Liu J; Li B; Shao Y; Xing J; Zhang S; Han P
Dis Markers; 2022; 2022():4959737. PubMed ID: 36118674
[TBL] [Abstract][Full Text] [Related]
29. New design of nucleotide excision repair (NER) inhibitors for combination cancer therapy.
Gentile F; Tuszynski JA; Barakat KH
J Mol Graph Model; 2016 Apr; 65():71-82. PubMed ID: 26939044
[TBL] [Abstract][Full Text] [Related]
30. Evidence for in the appearance of mRNAs of nucleotide excision repair genes, in human ovarian cancer tissues.
Reed E; Dabholkar M; Thornton K; Thompson C; Yu JJ; Bostick-Bruton F
Oncol Rep; 2000; 7(5):1123-8. PubMed ID: 10948350
[TBL] [Abstract][Full Text] [Related]
31. An investigation of the molecular basis for the synergistic interaction of tirapazamine and cisplatin.
Goldberg Z; Evans J; Birrell G; Brown JM
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):175-82. PubMed ID: 11163512
[TBL] [Abstract][Full Text] [Related]
32. Nucleotide excision repair: why is it not used to predict response to platinum-based chemotherapy?
Bowden NA
Cancer Lett; 2014 May; 346(2):163-71. PubMed ID: 24462818
[TBL] [Abstract][Full Text] [Related]
33. Regulation of cisplatin resistance and homologous recombinational repair by the TFIIH subunit XPD.
Aloyz R; Xu ZY; Bello V; Bergeron J; Han FY; Yan Y; Malapetsa A; Alaoui-Jamali MA; Duncan AM; Panasci L
Cancer Res; 2002 Oct; 62(19):5457-62. PubMed ID: 12359753
[TBL] [Abstract][Full Text] [Related]
34. Lactacystin enhances cisplatin sensitivity in resistant human ovarian cancer cell lines via inhibition of DNA repair and ERCC-1 expression.
Li QQ; Yunmbam MK; Zhong X; Yu JJ; Mimnaugh EG; Neckers L; Reed E
Cell Mol Biol (Noisy-le-grand); 2001; 47 Online Pub():OL61-72. PubMed ID: 11936875
[TBL] [Abstract][Full Text] [Related]
35. XPA versus ERCC1 as chemosensitising agents to cisplatin and mitomycin C in prostate cancer cells: role of ERCC1 in homologous recombination repair.
Cummings M; Higginbottom K; McGurk CJ; Wong OG; Köberle B; Oliver RT; Masters JR
Biochem Pharmacol; 2006 Jul; 72(2):166-75. PubMed ID: 16756962
[TBL] [Abstract][Full Text] [Related]
36. XPA protein as a limiting factor for nucleotide excision repair and UV sensitivity in human cells.
Köberle B; Roginskaya V; Wood RD
DNA Repair (Amst); 2006 May; 5(5):641-8. PubMed ID: 16413230
[TBL] [Abstract][Full Text] [Related]
37. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M
Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719
[TBL] [Abstract][Full Text] [Related]
38. Interrelationships between cellular nucleotide excision repair, cisplatin cytotoxicity, HER-2/neu gene expression, and epidermal growth factor receptor level in non-small cell lung cancer cells.
Tsai CM; Chang KT; Li L; Perng RP; Yang LY
Jpn J Cancer Res; 2000 Feb; 91(2):213-22. PubMed ID: 10761709
[TBL] [Abstract][Full Text] [Related]
39. Expression of nucleotide excision repair proteins in lymphocytes as a marker of susceptibility to squamous cell carcinomas of the head and neck.
Wei Q; Wang LE; Sturgis EM; Mao L
Cancer Epidemiol Biomarkers Prev; 2005 Aug; 14(8):1961-6. PubMed ID: 16103444
[TBL] [Abstract][Full Text] [Related]
40. [Relationship between nucleotide excision repair gene ERCC1 and resistance to cisplatin in ovarian cancer].
Liu GY; Qu QX; Mi RR; Qi J
Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):184-7. PubMed ID: 18756932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
